Clinical Trials Browser

Phase 3 × Prostate Cancer Metastatic × darolutamide × Clear all

NCT04916613 2024-09-26

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Phase 3 Recruiting

Prostate Cancer Metastatic